Anti-neoplastic antibiotic. Inhibits DNA-primed RNA polymerase by complexing with DNA via deoxyguanosine residues. At higher concentrations, DNA polymerase is inhibited. Also acts as a competitive inhibitor of serine proteases. Inhibits cell growth and colony formation in synchronized HeLa cells. Induces apoptosis in many cell lines. However, actinomycin D has also been shown to suppress etoposide-induced apoptosis in PC12 cells. Note: 1 set = 20 x 200 µg.

Antineoplastic antibiotic. Inhibits DNA-primed RNA polymerase by complexing with DNA via deoxyguanosine residues. A DNA-intercalator with growth inhibitory activity against certain leukemias and sarcomas. At higher concentrations, DNA polymerase is inhibited. Inhibits cell growth and colony formation in synchronized HeLa cells. A potent inducer of apoptosis in many cell lines; however, actinomycin D has also been shown to suppress programmed cell death of PC12 cells induced by etoposide, an inhibitor of topoisomerase II. Acts as a competitive inhibitor of serine protease from microorganisms. The growth of S. aureus is inhibited by 0.25-0.75 µg/ml, whereas a concentration of 100 µg/ml is required to inhibit E. coli due to permeability differences. Heat resistant and stable between pH 2 and 11; decomposed by strong acids and bases. λ_max 441 nm ±2 nm. Note: 1 set = 20 vials x 200 µg.

Stability: heat resistant and stable between pH 2 and 11. Decomposed by strong acids and bases.

Primary Target
serine proteases

Secondary Target
cell growth and colony formation in synchronized HeLa cells

Following reconstitution, aliquot and freeze (-20°C) for long term storage or refrigerate (4°C) for short term storage. Stock solutions are stable for up to 3 months at -20°C.

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Nakajima, M., et al. 1994. Neurosci. Lett.176, 161.
Wu, M.H., and Yung, B.Y. 1994. Eur. J. Pharmacol. 270, 203.
Betzel, C., et al. 1993. Biochim. Biophys. Acta 1161, 47.
Yung, B.Y., et al. 1992. Int. J. Cancer52, 317.
Martin, S.J., et al. 1990. J. Immunol.145, 1859.
Yung, B.Y., et al. 1990. Cancer Res.50, 5987.
White, R.J., and Phillips, D.R. 1985. Biochemistry27, 9122.
Madharavao, M., et al. 1978. J. Med. Chem.21, 958.
Sengupta, S.K., et al. 1975. J. Med. Chem.18, 1175.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Highly Toxic & Carcinogenic / Teratogenic (I)